Coupon Accepted Successfully!


Recent Advances: Endocrine

Bromocriptine; Approved for use in T2DM. While the exact mechanism remains to be elucidated, the known activity of bromocriptine through dopamine agonism may modulate CNS regulatory pathways of glucose and energy metabolism.
Linagliptin: It is a newer orally-active inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme It is approved for type 2 diabetes mellitus. Major adverse effect of this drug include nasopharyngitis, hypoglycemia and pancreatitis
Tocilizumab: It is a recombinant humanized monoclonal antibody against IL-6 receptors. It is specifically indicated for the treatment of active systemic juvenile idiopathic arthritis in patients two years of age and older
Icatibant: It is a competitive antagonist selective for the bradykinin B2 receptor. It is approved for the treatment of acute attacks of hereditary angioedema in adults.
Zoledronic acid: Only Once-yearly osteoporosis treatment approved for prevention of fractures after a hip fracture
Pegvisomant: GH receptor antagonist used in the treatment of acromegaly.
Dronedarone: An antiarrhythmic drug indicated to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter

Test Your Skills Now!
Take a Quiz now
Reviewer Name